No Data
No Data
No Data
No Data
No Data
Express News | Fosun Pharmaceuticals: The holding subsidiary received approval for the registration of cycloserine capsules
BreakingsApr 24 17:02
復星醫藥:二零二三年年報
Futu NewsApr 24 16:44 · Announcements
A record high! Fosun Pharmaceutical (02196) was selected as one of the top 20 global pharmaceutical companies in terms of pipeline size
For the third year in a row, Fosun Pharmaceutical (02196) was selected as one of the top 25 pharmaceutical companies in the world, ranking 17th, up 7 places from the previous year.
Zhitong FinanceApr 23 17:42
Fosun Pharmaceutical (02196.HK): Investment funds participating in the establishment completed private equity fund filing
Gelonghui, April 22, 丨 Fosun Pharmaceutical (02196.HK) announced that on March 30, 2023, the company's holding subsidiary/enterprise Shanghai Fuyu Shengjian Enterprise Management Partnership (Limited Partnership) (hereinafter referred to as “Fuyu Shengjian”), Ningbo Fuying Investment Co., Ltd. (hereinafter referred to as “Ningbo Fuying”) and other 2 investors signed the “Anji Fuyu Chengxiang Venture Capital Partnership (Limited Partnership) Limited Partnership” with other investors to jointly fund the establishment of Anji Fucheng Yuxiang Venture Capital Partnership (Limited Partnership) “Equipment Fund”); same day, Company holding subsidiaries/corporate recovery
Gelonghui FinanceApr 22 17:43
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy
China's drug regulator granted clinical trial approval to a Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) subsidiary for its HLX53 combination with slulimumab and bevacizumab injections
MT NewswiresApr 18 17:51
Featured announcements | Xiaopeng and Volkswagen reached a strategic technical cooperation; Sands China's total net revenue increased 42% year over year
Anta Sports: The retail value of Anta brand products achieved a positive year-on-year increase in the number of units in the first quarter; China Building Materials expects a 147% year-on-year increase in net loss for the first quarter.
cls.cnApr 18 08:10
No Data
No Data